<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130628">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01401452</url>
  </required_header>
  <id_info>
    <org_study_id>P12-770</org_study_id>
    <nct_id>NCT01401452</nct_id>
  </id_info>
  <brief_title>Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities</brief_title>
  <acronym>EPIC</acronym>
  <official_title>Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Raffeiner GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this post-marketing observational study (PMOS) is the assessment of effectiveness
      of Adalimumab in moderate to severe Plaque Psoriasis patients with distinct co-morbidities
      and impact of Adalimumab on the quality of life in routine clinical praxis over the period
      of 9 month. Psoriasis is associated with several co-morbidities such as depression, obesity
      and metabolic syndrome. Until now it is unclear if these co-morbidities are due to the
      pathophysiology of psoriasis or psoriasis-associated behaviors (e.g. smoking and alcohol
      abuse). Disease severity is correlated with smoking and alcohol abuse. The severity of
      psoriasis shall be established before and under treatment of Adalimumab by calculation of
      the Psoriasis Area Severity Index (PASI) and the analysis of Dermatology Life Quality Index
      (DLQI) in Patients with at last one co-morbid disease and/or symptom. Also the prevalence of
      co-morbidities in consideration of gender and other parameters of Life Quality (SF-36) and
      Life-Quality for specific co-morbidities should be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effectiveness of Adalimumab over a period of 9 month by analyzing the Psoriasis Area &amp; Severity Index (PASI) in moderate to severe Plaque Psoriasis patients with distinct co-morbidities</measure>
    <time_frame>9 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Area &amp; Severity Index (PASI) (=Inclusion visit)</measure>
    <time_frame>12 month</time_frame>
    <description>Observation and assessment for erythema, induration (plaque thickness), and desquamation (scaling) as seen on the day of the examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Area &amp; Severity Index (PASI)</measure>
    <time_frame>month 1</time_frame>
    <description>Observation and assessment for erythema, induration (plaque thickness), and desquamation (scaling) as seen on the day of the examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Area &amp; Severity Index (PASI)</measure>
    <time_frame>month 3</time_frame>
    <description>Observation and assessment for erythema, induration (plaque thickness), and desquamation (scaling) as seen on the day of the examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Area &amp; Severity Index (PASI)</measure>
    <time_frame>month 6</time_frame>
    <description>Observation and assessment for erythema, induration (plaque thickness), and desquamation (scaling) as seen on the day of the examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Area &amp; Severity Index (PASI)</measure>
    <time_frame>month 9</time_frame>
    <description>Observation and assessment for erythema, induration (plaque thickness), and desquamation (scaling) as seen on the day of the examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) (=Inclusion visit)</measure>
    <time_frame>12 month</time_frame>
    <description>Subjects will complete a DLQI questionnaire at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Subjects will complete a DLQI questionnaire at study visits.</measure>
    <time_frame>month 1</time_frame>
    <description>Subjects will complete a DLQI questionnaire at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Subjects will complete a DLQI questionnaire at study visits.</measure>
    <time_frame>month 3</time_frame>
    <description>Subjects will complete a DLQI questionnaire at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Subjects will complete a DLQI questionnaire at study visits.</measure>
    <time_frame>month 6</time_frame>
    <description>Subjects will complete a DLQI questionnaire at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Subjects will complete a DLQI questionnaire at study visits.</measure>
    <time_frame>month 9</time_frame>
    <description>Subjects will complete a DLQI questionnaire at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the prevalence of co-morbidities in consideration of gender (=Inclusion visit)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality (=Inclusion visit)</measure>
    <time_frame>12 month</time_frame>
    <description>Evaluation of parameters of Life Quality (SF-36) and the Life-Quality for specific co-morbidities (optional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>month 1</time_frame>
    <description>Evaluation of parameters of Life Quality (SF-36) and the Life-Quality for specific co-morbidities (optional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>month 3</time_frame>
    <description>Evaluation of parameters of Life Quality (SF-36) and the Life-Quality for specific co-morbidities (optional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>month 6</time_frame>
    <description>Evaluation of parameters of Life Quality (SF-36) and the Life-Quality for specific co-morbidities (optional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>month 9</time_frame>
    <description>Evaluation of parameters of Life Quality (SF-36) and the Life-Quality for specific co-morbidities (optional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the minimum of clinical important differences (MCID) (=Inclusion visit)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the minimum of clinical important differences (MCID)</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the minimum of clinical important differences (MCID)</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the minimum of clinical important differences (MCID)</measure>
    <time_frame>month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the minimum of clinical important differences (MCID)</measure>
    <time_frame>month 9</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">246</enrollment>
  <condition>Moderate to Severe Plaque Psoriasis</condition>
  <condition>Antibodies</condition>
  <condition>Monoclonals</condition>
  <arm_group>
    <arm_group_label>Patients with psoriasis with at last one co-morbid disease</arm_group_label>
    <description>Patients with moderate to severe plaque psoriasis with at last one co-morbid disease and/or symptom such as hypertension, Psoriasis Arthritis confirmed by a rheumatologist, obesity, diabetes, metabolic syndrome or depression</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital, Dermatology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients for whom Adalimumab therapy is indicated and has been prescribed according to the
        product label and who meet the following criteria:

          -  Patients age &gt;= 18 years

          -  Moderate to severe Plaque Psoriasis patients with at last one co-morbid disease
             and/or symptom such as hypertension, Psoriasis Arthritis confirmed by a
             rheumatologist, obesity, diabetes, metabolic syndrome or depression.

          -  Adalimumab naïve patients with moderate to severe Plaque Psoriasis after
             unsatisfactory response or non tolerability or contraindication of systemic therapies
             such as ciclosporin, methotrexate or PUVA ( psoralen + UVA) or after biological
             disease modifying anti-rheumatic drugs (BDMARDs) failure (e.g.: infliximab,
             etanercept or ustekinumab)

          -  Patients must fulfill Austrian Treatment Recommendations for use of BDMARD in
             Psoriasis (Chest X-ray and IGRA* interferon gamma release assay or PPD-skin test
             negative for tuberculosis)

          -  Patient is willing to consent to data anonymous being collected and provided to
             Abbott.

          -  Patient must be able and willing to self-administer Adalimumab injections or have a
             qualified person available to administer Humira® syringe or Humira® Pen injections.

        Exclusion Criteria:

        The following patients will not be included in this observational study:

          -  Patients who meet contraindications as outlined in the latest version of the Humira
             syringe® Summary of Product Characteristics (SPC) and Humira Pen® SPC.

          -  Patients participating in another study program or clinical trial.

          -  Patients who have been treated with Humira® before.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Dorr, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67422</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 80173</name>
      <address>
        <city>Laakirchen</city>
        <zip>4663</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67426</name>
      <address>
        <city>St. Poelten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67425</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67423</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67424</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 69663</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 49966</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67427</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129916</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129915</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104339</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104337</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104335</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104595</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116381</name>
      <address>
        <city>Heraklion Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104596</name>
      <address>
        <city>Larissa</city>
        <zip>41100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104597</name>
      <address>
        <city>Pireas</city>
        <zip>18536</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104336</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54643</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104338</name>
      <address>
        <city>Thessaloniki</city>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102741</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102735</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102742</name>
      <address>
        <city>Kiryat Bialik</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102737</name>
      <address>
        <city>Netivot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131666</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102758</name>
      <address>
        <city>Lisbon</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102757</name>
      <address>
        <city>Lisbon</city>
        <zip>1169-050</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102756</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144489</name>
      <address>
        <city>Lisbon</city>
        <zip>1998-018</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102744</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102743</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102755</name>
      <address>
        <city>Santarem</city>
        <zip>2005-177</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 102745</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4400-129</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Portugal</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 24, 2016</lastchanged_date>
  <firstreceived_date>July 1, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monoclonals</keyword>
  <keyword>Moderate to severe plaque psoriasis</keyword>
  <keyword>Psoriasis Area &amp; Severity Index (PASI)</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Biological disease modifying anti-rheumatic drugs (BDMARD)</keyword>
  <keyword>Co-morbidities</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Disease Life Quality Index (DLQI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
